



Sociedade
Brasileira de
Infectologia

Contents lists available at ScienceDirect

Brazilian Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/bjid



Brief Communication

Increased rates of *bla*_{NDM} in *Pseudomonas aeruginosa* in a tertiary care hospital in southern Brazil

Patricia Orlandi Barth^{a,b,*}, Dariane Castro Pereira^a, Camila Mörschbacher Wilhelm^a,
Kellen Figueira Tragnago^a, Afonso Luís Barth^{a,b}

^a Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

^b Universidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Ciências Médicas (PPGCM/UFRGS), Porto Alegre, RS, Brazil



ARTICLE INFO

Keywords:

Pseudomonas aeruginosa Carbapenemases
NDM

ABSTRACT

Carbapenem-Resistant *Pseudomonas Aeruginosa* (CRPA) is considered as one of the high priority pathogens by the World Health Organization. As CRPA carbapenemase producers have increased worldwide, the aim of this study was to evaluate the carbapenemase prevalence in CRPA at a tertiary care hospital in Brazil. All 395 CRPA identified in the period of September 2021 to May 2024 were evaluated by multiplex real-time polymerase chain reaction (qPCR-HRM) for the following carbapenemase genes: *bla*_{KPC}, *bla*_{NDM}, *bla*_{OXA-48-like}, *bla*_{IMP}, *bla*_{VIM}, *bla*_{SPM} and *bla*_{GES}. In the first period analyzed (September to December 2021), almost 70 % of the isolates were negative for the 7 tested genes, and the *bla*_{NDM} was found in 27.3 % of the CRPA. In the following semesters there was an increase of *bla*_{NDM} as follows: January to June of 2022 = 29.8 %; July to December of 2022 = 43.8 %; January to June of 2023 = 42.4 %; July to December 2023 = 58.9 % and January to May of 2024 = 59.5 % of *bla*_{NDM}. The prevalence of the other carbapenemases remained low. These results indicated an important increase of the *bla*_{NDM} gene, overcoming the CRPA non-carbapenemase producers in our institution.

Pseudomonas aeruginosa is a non-fermenting gram-negative bacilli typically found in healthcare settings, usually associated with urinary tract, respiratory and bloodstream infections [1] Carbapenem-Resistant *P. Aeruginosa* (CRPA) is particularly worrying and is considered a high-priority pathogen in the 2024 Bacterial Priority Pathogens List due to their global threat and limited therapeutic options [2] Furthermore, CRPA are associated with worse morbidity and mortality outcomes compared to susceptible isolates, as well as an important impact on hospitalization costs [3,4]

The main mechanisms which lead to carbapenem resistance in *P. aeruginosa* are efflux pump overexpression, overproduction of AmpC beta-lactamase usually associated with porin loss or inactivation, and, more rarely, production of carbapenemases [5] While the most prevalent carbapenemase gene worldwide are *bla*_{VIM} followed by *bla*_{GES} [6] *bla*_{NDM} has been emerging in the last years in CRPA from Europe [7] Africa [8] and other countries [9]

Until 2010, the *bla*_{SPM} gene used to be the most common carbapenemase among CRPA in southern Brazil [10,11] However, a shift from *bla*_{SPM} to other carbapenemase genes, including *bla*_{NDM}, was described in the last three years [12] The increasing rates of *bla*_{NDM} is highly

alarming, as this gene is commonly associated with resistance to carbapenems and other antimicrobial classes[13,14] which limits treatment options. Therefore, the aim of this study was to evaluate carbapenemase prevalence in CRPA clinical isolates from a tertiary care hospital in southern Brazil.

All CRPA (only one isolate per patient) identified at the Microbiology Laboratory of Hospital de Clínicas de Porto Alegre during the period of September 2021 to May 2024 were evaluated for carbapenemase genes by multiplex real-time Polymerase Chain Reaction (qPCR) using High-Resolution Melting (HRM) analysis for *bla*_{SPM}, *bla*_{KPC}, *bla*_{NDM}, *bla*_{OXA-48-like}, *bla*_{IMP}, *bla*_{VIM} and *bla*_{GES} as previously described [15] DNA was extracted by thermal lysis, and qPCR HRM was performed using QuantStudio-3® (Thermo Fisher). The identification of the isolates was performed by Matrix-Assisted Laser-Desorption Ionization Time-Of-Flight Mass Spectrometry – MALDI-TOF-MS (Bruker Daltonics) and resistance to carbapenems was determined by meropenem disk diffusion method [16]

In the period of this study, 395 CRPA isolates of *P. aeruginosa* were evaluated. A total of 218 (55.2 %) presented carbapenemase genes by qPCR HRM assays. In the second semester of 2021, when carbapenemase

* Corresponding author.

E-mail address: patybarth@hotmail.com (P.O. Barth).

<https://doi.org/10.1016/j.bjid.2025.104523>

Received 29 August 2024; Accepted 26 February 2025

Available online 10 April 2025

1413-8670/© 2025 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).




Fig. 1. Prevalence of carbapenemase genes in CRPA at Hospital de Clínicas de Porto Alegre – Brazil, from September 2021 to May 2024.

evaluation in CRPA initiated, almost 70 % (38/55) of isolates were negative for the 7 genes tested, and *bla*_{NDM} gene was detected in 27.3 % (15/55). In the following semesters, there was a steadily increasing of *bla*_{NDM} as follows: January to June of 2022 = 29.8 % (17/57) of *bla*_{NDM}; July to December of 2022 = 43.8 % (21/48); January to June of 2023 = 42.4 % (28/66); July to December 2023 = 58.9 % (53/90) and January to May of 2024 = 59.5 % (47/79) of *bla*_{NDM}. The prevalence of the other carbapenemases remained constant (Fig. 1).

The Brazilian Agency of Sanitary Surveillance issued a document of risk warning [17] for identification of *P. aeruginosa* resistant to carbapenems producing *bla*_{KPC} and *bla*_{NDM} in health care services in Brazil in September 2021 and since then we have been evaluated for carbapenemase genes all CRPA in our institution. Until recently, *bla*_{VIM} and *bla*_{IMP} were the most frequently carbapenemase found in CRPA worldwide, with *bla*_{SPM} maintaining regional spread in Brazil [18,19] This same picture was seen in southern Brazil and in our institution [10,11]

A study conducted in Brazil, between November 2015 and August 2016, evaluated 28 CRPA in hospitalized patients, and the main mechanism involved in carbapenem resistance was due to mutations in porin genes that altered expression levels, with low prevalence of carbapenemases and no *bla*_{NDM} detected [20] Another study, conducted by Kiffer et al., evaluated the prevalence of carbapenemases in Brazilian gram negative pathogens from 2015 to 2022. This study demonstrated a high prevalence of *P. aeruginosa* *bla*_{SPM} in 2015 (22.5 %) which decreased to around 10 % in 2016–2019 and to less than 5 % in 2020–2022. Noteworthy, the study of Kiffer et al., indicated that the *bla*_{NDM}, which was very uncommon before 2020, presented a steady increase from 2021 to 2022 (8.8 % and 6.9 %, respectively) [12]

In our study we found a significant increase, from September 2021 to May 2024, in carbapenemase in CRPA, markedly due to the *bla*_{NDM} gene. Conversely, CRPA without carbapenemase gene which accounted for around 70 % in September 2021 decreased significantly to less than 37 % in May 2024. Although we did not evaluate efflux pump and porin expression, our results demonstrate that CRPA in our institution are mostly carbapenemase producers, mainly due to the presence of the *bla*_{NDM} gene.

The data from our study is alarming as the treatment of CRPA *bla*_{NDM} would not respond to the treatment with the new beta lactam/beta lactamase combinations such as ceftazidime/avibactam, which has no activity against metallo enzymes such as NDM [21] Furthermore, while

*bla*_{SPM} was usually carried in plasmids not associated with other antimicrobial resistant genes,[18] *bla*_{NDM} was found in plasmids carrying genes that lead to resistance to aminoglycosides and fluoroquinolones [13,14]

This study reinforces the need for surveillance of local epidemiology and early detection of the molecular mechanism of CRPA to avoid the empirical treatment with ceftazidime/avibactam and to improve resources against these infections.

Conflicts of interest

The authors declare no conflicts of interest

Funding

This work has been funded by INPRA – Instituto Nacional de Pesquisa em Resistência Antimicrobiana – Brazil (INCT/CNPq: 465718/2014-0 and INCT/FAPERGS: 17/2551-0000514-7) and by Fundo de Incentivo à Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE/HCPA) (Project n° 2023-0014).

References

- Peix A, Ramirez-Bahena MH, Velázquez E. Historical evolution and current status of the taxonomy of genus *Pseudomonas*. *Infect Genet Evol*. 2009;9:1132e1147.
- Organization World Health. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance [Accessed August 6th]. Available from <https://www.who.int/publications/i/item/9789240093461>; 2024 May.
- Morata L, Cobos-Trigueros N, Martínez JA, Soriano A, Almela M, Marco F, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of *Pseudomonas aeruginosa* bacteremia. *Antimicrob Agents Chemother*. 2012;56:4833–4837.
- Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant gram-negative bacteria. *Front Cell Infect Microbiol*. 2022;12, 823684.
- Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing *Pseudomonas aeruginosa* – an emerging challenge. *Emerg Microbes Infect*. 2022;11:811–814.
- Gill CM, Nicolau DP. ERACE-PA Global Study Group. Carbapenem-resistant *Pseudomonas aeruginosa*: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients. *Antimicrob Resist Infect Control*. 2022;11:146.
- Torrens G, Van Der Schalk TE, Cortes-Lara S, Timbermont L, Barrio-Tofiño ED, Xavier BB, et al. Susceptibility profiles and resistance genomics of *Pseudomonas aeruginosa* isolates from European ICUs participating in the ASPIRE-ICU trial. *J Antimicrob Chemother*. 2022;77:1862–1872.

8. Gill CM, Aktaj E, Alfouzan W, Bourassa L, Brink A, Burnham CD, et al. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro activity against a Global collection of carbapenem-resistant *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis*. 2021;40:2533–2541.
9. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators. Global epidemiology and clinical outcomes of carbapenem-resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort study. *Lancet Microbe*. 2023;4:e159–e170.
10. Zavascki AP, Gaspareto PB, Martins AF, Gonçalves AL, Barth AL. Outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing SPM-1 metallo- β -lactamase in a teaching hospital in southern Brazil. *J Antimicrob Chemother*. 2005;56:1148–1151.
11. Martins AF, Zavascki AP, Gaspareto PB, Barth AL. Dissemination of *Pseudomonas aeruginosa* producing SPM-1-like and IMP-1-like metallo-beta-lactamases in hospitals from southern Brazil. *Infection*. 2007;35:457–460.
12. Kiffer CRV, Rezende TFT, Costa-Nobre DT, Marinonio ASS, Shiguenaga LH, Kulek DNO. A 7-year Brazilian national perspective on plasmid-mediated carbapenem resistance in *enterobacterales*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* complex and the impact of the Coronavirus Disease 2019 pandemic on their occurrence. *Clin Infect Dis*. 2023;77(Suppl 1):S29–S37.
13. Jain A, Hopkins KL, Turton J, Doumith M, Hill R, Loy R, et al. NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. *J Antimicrob Chemother*. 2014;69:1777–1784.
14. Findlay J, Poirel L, Kessler J, Kronenberg A, Nordmann P. New Delhi metallo- β -lactamase–Producing enterobacterales bacteria, Switzerland, 2019–2020. *Emerg Infect Dis*. 2021;27:2628–2637.
15. Monteiro J, Widen RH, Pignatari ACC, Kubasek C, Silbert S. Rapid detection of carbapenemase genes by multiplex real-time PCR. *J Antimicrobi Chemother*. 2012;67:906–909.
16. EUCAST. European Committee on Antimicrobial Susceptibility Testing. Breakpoints tables for interpretation of MICs and zone diameters. *EUCAST*. 2024;0:2024. Version 14.
17. Comunicado de risco GVIMS/GGTES/ANVISA N° 01/2021 (01/09/2021). Identificação de *Pseudomonas aeruginosa* resistente a carbapenêmicos, produtora de KPC e NDM em serviços de saúde. 2021 sep [Accessed August 6th 2024]. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/comunicados-de-risco-1/comunicado-de-risco-01_2021-gvims-ggtes_01-09-2021.pdf.
18. Yoon EJ, Jeong SH. Mobile carbapenemase genes in *Pseudomonas aeruginosa*. *Front Microbiol*. 2021;12, 614058.
19. Halat HD, Moubareck AC. The intriguing carbapenemases of *Pseudomonas aeruginosa*: current status, genetic profile, and global epidemiology. *Yale J Biol Med*. 2022;95:507–515.
20. Souza GHA, Rossato L, Brito GT, Bet GMDS, Simionatto S. Carbapenem-resistant *Pseudomonas aeruginosa* strains: a worrying health problem in intensive care units. *Rev Inst Med Trop Sao Paulo*. 2021;63:e71.
21. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. *J Glob Antimicrob Resist*. 2020;22:18–27.